BYSI Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 mai 2024 @ 22:00):

Stats
Dagens volum	45 339.00
Gjennomsnittsvolum	225 248
Markedsverdi	87.78M
EPS	$0 ( 2024-05-03 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-4.17
ATR14	$0.0290 (1.27%)

BeyondSpring Inc Korrelasjon

10 Mest positive korrelasjoner
INTZ	0.941
PRAX	0.936
QRTEA	0.932
AIHS	0.927
ERIE	0.924
RUBY	0.923
VVOS	0.922
VERU	0.921
JAGX	0.92
SOUN	0.919

10 Mest negative korrelasjoner
KNBE	-0.922
TIG	-0.912
SNCR	-0.906
SGEN	-0.896
XEL	-0.893
SABR	-0.892
ORTX	-0.889
DCRC	-0.888
CCRC	-0.884
XM	-0.879

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

BeyondSpring Inc Korrelasjon - Valuta/Råvare

-0.17
( neutral )

-0.53
( weak negative )

0.00
( neutral )

-0.52
( weak negative )

0.68
( moderate )

0.63
( weak )

BeyondSpring Inc Økonomi

Annual	2023
Omsetning:	$1.75M
Bruttogevinst:	$1.75M (100.00 %)
EPS:	$-0.540

FY	2023
Omsetning:	$1.75M
Bruttogevinst:	$1.75M (100.00 %)
EPS:	$-0.540

FY	2022
Omsetning:	$1.35M
Bruttogevinst:	$1.35M (100.00 %)
EPS:	$-0.930

FY	2021
Omsetning:	$1.35M
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-2.14

Financial Reports:

No articles found.

BeyondSpring Inc

BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and for treatment of later-stage non-small cell lung cancer. It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab, a PD-1 antibody for the treatment of NSCLC; nivolumab and ipilimumab, a CTLA-4 antibody for the treatment of SCLC; and in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers. In addition, the company engages in the development of three small molecule immune agents in preclinical stages; and a drug development platform. The company was founded in 2010 and is headquartered in New York, New York.